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Abstract 
 
 Cancer drugs have among the lowest response rates across all diseases. Combining the 
wealth of omics data and machine learning is a promising way to reach this goal. In this thesis, 
we addressed the following aspects of precision oncology: (i) We used Macau, a bayesian 
multitask multi-relational algorithm to explore the associations between the drugs’ targets and 
signaling pathways’ activation. We applied this methodology to drug synergy prediction and 
stratification. (ii) We leveraged through a collaborative machine learning competition to 
understand the association between genome, transcriptome and proteome in tumors. The main 
focus of this thesis is to use machine learning to generate actionable insights, for more 
personalized therapies. 
 
 
Zusammenfassung 
 
 Die Ansprechrate bei Krebstherapeutika ist im Vergleich zu anderen Arzneimitteln niedrig. Die 
Kombination aus Omics-Daten und maschinellem Lernen ist ein vielversprechender Weg um 
eine höhere Ansprechrate zu erlangen. In dieser Arbeit haben wir uns mit den folgenden 
Aspekten der Präzisions-Onkologie befasst: (i) Wir verwendeten Macau, einen multi-relationalen 
bayesianischen Multitasking-Algorithmus, um die Assoziation zwischen den Zielproteinen und 
der Aktivierung von Signalwegen zu untersuchen. Diese Methode haben wir  zur Vorhersage 
und Stratifizierung von Synergien zwischen Medikamenten angewendet. (ii) Wir nutzten einen 
kollaborativen Wettbewerb zum maschinellen Lernen, um die Assoziation zwischen Genom, 
Transkriptom und Proteom in Tumoren zu verstehen. Der Schwerpunkt dieser Arbeit liegt auf 
dem Gewinnung wertvoller Erkenntnisse für personalisierte Therapien mit Hilfe von 
maschinellem Lernen. 
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General introduction 
 
 Precision medicine, also called "personalized medicine" is based on the customization of 
diagnosis and treatment according to molecular, genetic, transcriptomic and epigenetic 
information of the patient. This implies that patients are fundamentally different and therefore 
should be treated differently. Instead of the “one size for all” paradigm that ruled the 
pharmaceutical industry for decades, we are switching to the development of drugs which are 
efficient for only a subset of patients. With increasing spending in drug development industry 
due to adverse events of lack of efficacy, targeted therapies are evermore needed. Indeed, a 
drug that is toxic for one may be safe for another. Similarly, a drug that is ineffective for one may 
be effective for another. Different classes of targeted therapies are available in oncology 
(https://www.cancer.gov): hormone therapies, signal transduction inhibitors, gene expression 
modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery 
molecules. 
 
 In precision oncology, the therapeutic success for one patient can be used in a accurate way 
for many other patients whose tumors have a similar genetic profile. For instance, in breast 
cancer, a patient receives a standard chemotherapy, followed by remnography (MRI) to 
measure the efficacy. We now aim at including a genomic analysis of the breast tumor biopsy to 
choose a suitable combination therapy tailored to her genetic profile. This new approach adds 
several levels of information: a unique genetic profile, early MRI tracking, real-time assessment 
of the effectiveness of treatment, and the ability to respond quickly to new omics data.  
 
 The major technological advances of recent years have undeniably contributed in the rise of 
this new therapeutic approach. The decrease in the costs of sequencing of the human genome 
and custom analyzes such as DNA microarrays are examples of such advances. There are at 
least three essential implications in this metamorphosis of medical practices: (i) The first relates 
to the technological challenges necessary for this practice, such as bioinformatics 
infrastructures, in order to process genomic information in real time to guide the patient's 
treatment, as well as the power of the genome sequencing machines. (ii) The second is the 
training of the staff. Nowadays, it is essential to promote interdisciplinarity and a transversal 
approach to knowledge, e.g. to train highly qualified people in two or three fields of expertise. 
(iii) Finally, fundamental application of bioinformatics and machine learning in knowledge 
discovery. In this thesis, we will focus on the application of machine learning in deriving 
therapeutic insights for cancer. 
 
 We will present different projects to illustrate the role of machine learning and bioinformatics in 
precision oncology. The first project involves using matrix factorization to explore the underlying 
associations in cancer drug screenings (Yang et al. 2018a). We applied this concept in 
predicting drug combination synergy in breast and colorectal cancer. In this case, machine 
learning is used to generate hypothesis instead of purely prediction. In a second project, we 
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organized the NCI-CPTAC Proteogenomics challenge to understand the interplays between 
mRNA and protein level in breast and ovarian tumors.  
 
 Cancer cell lines have been the workhorse of preclinical study in oncology. Machine learning is 
widely used to predict drug response on the treated cell lines. However, insights derived from 
such studies usually refer to single drug-gene association. If the drug is a MEK inhibitor and the 
gene belongs to the MAPK pathway, researchers could report a relationship between MEK and 
MAPK. But it is not a direct and quantifiable association between protein MEK and MAPK 
pathway with respect to drug response. There is currently no such analysis regarding 
association between the features of the drug and the features of the cell lines. In order to 
directly capture the interaction between a protein target and a gene/pathway, we used Macau 
(Simm et al. 2017a), a matrix factorization type algorithm especially suited for cancer drug 
screening data. In a real life scenario, such interactions could answer the question: “which type 
of person likes which type of movie ?”, instead of a simpler high level association such as 
“which person likes which movies ?”. We analyzed the Genomics of Drug Sensitivity in Cancer 
(GDSC) (Iorio et al. 2016a) data, on 16 different cancer types and explored the interactions 
between drug targets and signaling pathways’ activations.  
 
 We applied this concept to drug synergy prediction and stratification. Cancer monotherapies 
are hampered by the ability of tumor cells to escape inhibition through rewiring or alternative 
pathways. Therefore, smart drug combination approaches are essential in controlling cancer 
proliferation and survival. We present two complementary workflows: One for prioritising drug 
synergy enrichment in high-throughput screens, and a consecutive workflow to predict 
hypothesis-driven patient stratification. Both workflows rely on bayesian matrix factorization to 
explore mechanistic relations between pathway activations derived from gene expression 
profiles and putative drug targets. We introduce the notion of Target functional similarity 
between 2 protein targets, which reflects how similarly effective drugs are as a function of 
targeted signaling pathway activities. Our synergy prediction workflow revealed that two drugs 
targeting the same or functionally opposite pathways are more likely to be synergistic, enabling 
experimental prioritisation in high-throughput screens and furthermore supporting the notion that 
synergy can be achieved by either redundant pathway inhibition or targeting independent 
compensatory mechanisms. We tested our synergy stratification workflow on a drug 
combination dataset for 7 pairs of protein targets (AKT/ALK, AKT/MTOR, AKT/EGFR, 
BCL2/MTOR, EGFR/MTOR and AKT/BCL2) applied to 33 breast cancer cell lines. For 
performance metric, we used the Pearson’s correlation of observed versus predicted synergy 
scores. We were able to reach an average drug-wise correlation of 0.27. We next 
experimentally validated our synergy stratification workflow with a BRAF/Insulin Receptor 
combination (Dabrafenib/BMS−754807) in 48 colorectal cancer cell lines. The performance is 
0.31 for all 48 cell lines and 0.4 by taking into account KRAS status. The synergy prediction 
workflow can be a powerful framework for compound prioritization in large scale drug 
screenings. For instance, only testing drugs targeting two functionally very similar or very 
distinct proteins could significantly reduce the search space. The synergy stratification workflow 
could potentially maximize the drug efficacy of drugs already known for inducing synergy. 
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 Signaling molecules, as well as most cancer drugs bind to protein receptors. If a protein is the 
most predictive of patient outcome, then making therapeutic decision based on the 
corresponding mRNA may be a mistake. Therefore, it is essential to characterize protein level to 
the best of our abilities. For this purpose, we launched a community-based collaborative 
competition: The NCI-CPTAC DREAM Proteogenomics Challenge. The challenge used public 
and novel proteogenomic data generated by the CPTAC to answer fundamental questions 
about how different levels of biological signal relate to one another. In particular, in Proteomics 
subchallenge we focused on the question: Can one predict abundance of any given protein from 
mRNA and genetic data? We predict the protein abundance based on mRNA and/or other 
molecular data. Proteins being the product of mRNA translation, there should be correlation 
between mRNA level and protein abundance. In cases where mRNA expression does not 
correlate with protein level, we explored through machine learning the potential post 
translational modifications and protein regulations e.g. the effect of other proteins.  
 
 This thesis is structured as follow: beside the abstract and the general introduction, two main 
chapters are presenting the main projects of the PhD, as described previously. Each research 
project is structured as follow: Introduction, Result, Methods, Discussion and Supplementary 
information in the annexe. Figures and tables are named separately for each chapter. Finally, a 
general conclusion and future perspectives. 
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Chapter 1: Target functional similarity based workflows for 
drug synergy prediction and stratification 
 
 
 
  
 14 
1.1 Introduction 
 
 In the quest for clinical efficacy, drug combinations have been widely used in cancer therapies 
(Dry, Yang, and Saez-Rodriguez 2016a; Al-Lazikani, Banerji, and Workman 2012). Targeting a 
signaling pathway at one step may not be sufficient for reaching maximal effects on pathway 
inhibition. Resistance mechanisms to monotherapy can occur by activation of compensatory 
signaling, for example the activation of ERK signaling in melanoma when treated with BRAF 
inhibitors may lead to paradoxical activation of CRAF (Montagut et al. 2008). Targeting BRAF 
and downstream MEK at the same time proved to be beneficial for overall patient survival 
(Lopez and Banerji 2017), by inhibiting the initial BRAF driver mutation and paradox CRAF 
activation. Alternatively to inhibiting two key proteins within the same pathway, a common 
strategy is to parallel inhibit two separate cancer pathways to maximise drug efficacy. For 
example, parallel inhibition of ERK and AKT could be beneficial as those pathways may be 
connected through cross talks and feedback loops in breast cancer (Saini et al. 2013). 
 
 Many methods predict drug synergy using chemical structure and genomic information (Bulusu 
et al. 2016; Bansal et al. 2014; Preuer et al. 2017). Drug chemical structure does not reflect the 
drug’s mode of actions as well as the putative drug targets (Yang et al. 2018b). Preuer et al. 
used deep learning to predict synergy within the space of explored drugs and cell lines, but still 
underperformed in predicting untested drugs on untested cell lines (Preuer et al. 2017), with 
mean square errors (MSEs) of 255 versus 414. One common bottleneck for the application of all 
those methods is the limited publicly available training set. Jaeger et al identified new drug 
combinations using network topology of pathway cross-talk (Jaeger et al. 2017), however, they 
did not consider gene mutation, which could be highly relevant in cancer treatment. Synergy is 
not a universal property of the drugs’ chemical structures but also highly context dependent 
(Sun et al. 2015). 
 
 In the recent Dialogue on Reverse-Engineering Assessment and Methods (DREAM) drug 
combination challenge (Menden et al. 2017a), led by AstraZeneca, the best performing team 
used a mouse protein-protein interaction network to augment the genomic features based on 
their network distance from drug targets. Whilst the best performer achieved outstanding 
predictability on level of experimental replicates, synergy was predicted based on supervised 
machine learning algorithms. Sparsity in the DREAM training dataset was expert-knowledge 
driven, and therefore may bias towards biological known and ultimately bias the performance of 
supervised learning. In practice, the combinatorial explosion of drug pairs is the limiting factor to 
both the number of experimentally tested drugs, as for the number of tested cell lines. Finally, 
knowledge based cancer gene sets have been used to enhance predictive models. However 
such methods have been demonstrated to be less informative than data derived gene sets 
(Cantini et al. 2018; Schubert et al. 2018). 
 
 We here propose a methodology for identifying increased synergy likelihood based on the 
notion of target functional similarity and being independent from combinatorial experiments. This 
entity reflects how similarly effective drugs with common target are, as a function of signaling 
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pathways’ activities. Two target proteins that are functionally very similar are likely to belong to 
the same signaling pathway. We argue that functional similarities between protein targets shed 
light on different synergy mechanisms. We then use the resulting mechanisms to build models 
to predict synergy. Thus, our prediction model is hypothesis derived and does not originate from 
a training set of drug synergy. We applied our methodology to the AstraZeneca breast dataset 
for drug synergy prediction (Menden et al. 2017a) and experimentally validated on predicted 
drug combination in colorectal cancer cell lines. In the process of synergy prediction, we 
revealed different synergy mechanisms depending on the cancer type. 
 
1.2 Results 
1.2.1 Synergy prediction workflow 
 We propose a workflow for highlighting synergy enrichment (Figure 1), based on multitask 
learning including the following steps: 1) We compute the pathway activity from gene expression 
using Pathway RespOnsive GENes (PROGENy) (Schubert et al. 2018). 2) Next, we apply the 
Macau algorithm (Simm et al. 2017b) to find interactions between the drugs’ nominal targets 
and pathway activities i.e. how targeting a protein may affect different signaling pathways(Yang 
et al. 2018b) (Methods). 3) We then use the previously determined interactions to compute the 
functional similarity between two protein targets i.e how similar are the system’s responses 
when targeting those two proteins. 4) Finally, functional similarity between protein targets 
pointing to different synergy mechanisms is estimated. This synergy prediction workflow allows 
for any given pair of protein targets, to estimate the likelihood of inducing synergy when 
targeting those 2 proteins. Our method returns a ranking of experimentally untested drug 
combinations from being likely to unlikely synergistic, which ultimately enables a prioritization for 
future experiments.  
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Figure 1: Methodology for drug synergy prediction and stratification. 
(a) First, we reduce gene expression of cancer cell lines of single compound drug screening, 
into a small subset of pathway activities. It consists in multiplying the transcriptomics data by a 
loading matrix, as described in Schubert et al. 
(b) We then use Macau algorithm(Simm et al. 2017c) to predict multiple drugs’ responses 
simultaneously by uncovering the common (latent) features that can benefit each individual 
learning task. We use the previously derived pathway scores as input features (side information) 
for cell lines, and nominal target for drugs. Each side information matrix is transformed into a 
matrix of L latent dimensions by a link matrix. Drug response is then computed by a matrix 
multiplication of the 2 latent matrices. 
(c) Concurrently to drug response prediction, we derive the interactions between drug features 
(targets) and cell line features (pathway activity), by multiplying the 2 link matrices. An 
association between protein X and pathway Y means that activation of pathway Y correlates 
with drug sensitivity when targeting protein X. In case of causality, we can say that activation of 
pathway Y confers sensitivity to any drug targeting protein X. 
(d) These interactions allow us to define the functional similarity between two protein targets. In 
this example of breast tissue, The functional similarity between proteins EGFR and AKT1 is the 
correlation of their interaction values with the 11 PROGENy pathways. As final step of the 
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synergy prediction workflow, the derived target functional similarity inform us about the 
likelihood of synergy.  
(e) For synergy stratification workflow, we start with target pairs already known to be synergistic. 
The value of the functional similarity between the protein targets reflects different synergy 
mechanisms. If the similarity is close to 1, synergy occurs by targeting the same signaling 
pathways. A similarity close to -1 suggests a synergy induced by compensation of escape 
mechanism. We build specific synergy model for each case to predict synergy scores of cancer 
cell lines. 
 
1.2.2 Pathway activities 
 
 We transformed the transcriptomics data into pathway activity scores using PROGENy 
(Schubert et al. 2018) (Figure 1a), a more recent version of the Signaling Pathway Enrichment 
using Experimental Data sets (SPEED) signatures (Parikh et al. 2010). PROGENy is a data 
driven pathway method aiming at summarizing high dimensional transcriptomics data into a 
small set of pathway activities. PROGENy derives pathway signatures from the genes that are 
altered when perturbing a pathway instead of solely from the genes within the pathway as other 
methods do. This improves the estimation of pathway activities (Schubert et al. 2018). The 11 
PROGENy pathways are EGFR, NFkB, TGFb, MAPK, p53, TNFa, PI3K, VEGF, Hypoxia, Trail 
and JAK-STAT. 
 
 
1.2.3 Interactions between drug target and pathway scores 
 
 We then computed the interactions between protein targets and signaling pathway activation 
status with respect to drug response (IC50) using matrix factorization (Figure 1b, 1c, Methods). 
This interaction can be defined as the importance for those two entities to be simultaneously 
involved in order to have an impact on drug response (Yang et al. 2018b), e.g. how the 
simultaneous activation of a certain pathway and targeting a certain protein can be associated 
with drug response. For instance, a strong interaction between protein MEK1/MEK2 and 
pathway EGFR in pancreatic cancer is interpreted as follows: Activation of the EGFR pathway 
correlates with sensitivity when targeting MEK1/MEK2. If this were a causal relationship, it could 
mean that EGFR pathway activation confers sensitivity to any drug targeting protein 
MEK1/MEK2. 
 
 We used the Genomics of Drug Sensitivity in Cancer (Iorio et al. 2016b) (GDSC) cell line panel 
that contains drug response (IC50) data of 265 drugs on 990 cell lines. For each of the 16 
tissues (with more than 20 cell lines), we computed the interaction matrix between drug targets 
and pathway activities using the multitask learning algorithm Macau (Simm et al. 2017b; Yang et 
al. 2018b). Our algorithm tries to learn multiple tasks (predicting multiple drugs) simultaneously 
and uncovers the common (latent) features that can benefit each individual learning task (Pan 
and Yang 2010).  We used manually curated protein targets for the drug (Supplementary 
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Table 3), and gene expression derived pathway scores for the cell lines. The interaction matrix 
gives hints about the drug’s mode of action, by uncovering in which condition (pathway status) 
targeting a certain protein correlates with higher drug sensitivity. 
 
 
1.2.4 Target functional similarity 
 
 Next, we studied how similar two targets are in terms of pathway level impact on drug 
response. We reasoned that we can use the correlation as an estimate of the functional 
similarity between two protein targets: high correlation being the most similar pair and high anti-
correlation being the most opposite pair. A pathway contains more information than a single 
gene’s expression level. Therefore, functional similarity based on a small subset of essential 
pathways is likely to be more robust than using thousands of genes, of which the vast majority 
are not involved in drug response. We considered the target pathway interaction matrix for 
breast tissue and 102 protein targets which are targeted by at least two drugs in the GDSC 
dataset. We selected the 25 protein targets from GDSC that are also part of the AstraZeneca 
drug combination challenge data (Figure 1d, Figure 2a).  There are 
(𝑛2
 
 − 𝑛) 
2 
= 300 pairwise 
combinations from the n=25 proteins. We then kept 99 target pairs where the two proteins are 
targeted by two different drugs in the GDSC panel. For each combination of targets, we 
computed the Pearson’s correlation of the interaction score with the 11 PROGENy pathways. 
The target combinations were then ranked from the most correlated pair to the most anti-
correlated pair. For instance, proteins BRAF and MEK have a functional similarity of 0.74 
(p=0.0088) in skin cell lines, which illustrates the synergy mechanism of inhibiting two key 
proteins within the same pathway. We consider a similarity greater than 0.7 to reflect similar 
effects upon perturbation of those targets that are closely related in the signaling cascade 
(Supplementary Figure 7 for distribution of similarity values). 
 
 Synergy scores in AstraZeneca breast dataset is derived from a dose-response surface of two 
drugs at different concentrations (Methods). A score of 50 is equivalent to an extra synergistic 
effect of 50% compared to the expected effect derived from the Loewe’s additivity model 
(Fitzgerald et al. 2006). To ascertain if target functional similarity can influence drug synergy, for 
each target pair, we plotted the observed average synergy scores of the top three ranked 
synergistic drug1-drug2-cell triplets, against it’s target functional similarity (Figure 2b). We 
observed that synergy arises in both highly correlated and highly anti-correlated target groups 
(Figure 2b). Very few synergistic target pairs were found with a functional similarity close to 
zero (lowly correlated target group). 
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Figure 2: Influence of the similarity between protein targets on drug synergy. (a) We 
selected common targets from AstraZeneca and GDSC data sets. (b) The target functional 
similarity is the correlation between 2 targets by their interactions with the PROGENy pathways. 
A correlation of 1 implies that the activities of pathways correlates in the same way with drug 
efficacy on those proteins. A correlation of -1 implies opposite effects. The average synergy is 
computed for each target pair, as the mean of the top three synergistic drug-cell line pairs. We 
chose a threshold of 20 as synergistic effect, and a score lower than -20 as antagonistic effect, 
as in Menden et al (Menden et al. 2017b). 
 
 
 We tested the significance of our observation on breast (33 cell lines), colon (12 cell lines) and 
NSCLC (22 cell lines), by computing the correlation between the top synergistic combinations 
and the absolute value of the target functional similarity (Supplementary Figure 1). For breast, 
colon and lung tissues, the Pearson’s correlations are r=0.25 (p=0.014), r=0.45 (p=0.27) and 
r=0.14 (p=0.56), respectively. Although not optimal, the trend is stronger for colon than for lung, 
which was the reason guiding our choice for colorectal cancer cell lines in experimental 
validation. 
 
 Target functional similarity is therefore a metric that can be used for compound prioritization. 
For any given target pair, along with single drug response, we can increase the likelihood of 
synergy. This is, the more functional similar or opposite two proteins are, the mostly likely 
synergy will arise.  We reason that this could be due to complementary mechanisms of synergy 
that take place:  
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Mechanism 1: When two drugs have similar interaction profiles, they are most likely targeting 
some common mechanism. In this case, synergy may be achieved by double hit of the same 
pathway. Mechanism 2: Conversely, targeting one protein may lead to resistance by an escape 
pathway or feedback loop. Targeting another protein which has opposite functional similarity 
may act on the escape pathway. Here, synergy reflects a compensation of escape mechanisms. 
1.2.5 Synergy stratification workflow 
 
 As an addition to the synergy prediction workflow, we propose a consecutive step, which 
enables patient stratification. For this, we use the inferred synergy mechanism and pathway 
activities of new samples to build specific models to predict synergy for new drug combinations. 
The synergy stratification workflow predicts the actual synergy scores on samples for a given 
target pair for which synergy has been described (either through experiments or from literature). 
 
 
Synergy stratification for each model 
 
 For each of the previously described synergy mechanisms (Figure 1e), we built models to 
predict synergy scores on cancer cell lines. We only consider drug combination known to induce 
synergy, for several reasons: (i) Our method relies heavily on literature/pathway knowledge, 
therefore difficult to test on all drug pairs. (ii) Synergy stratification when there is no synergy can 
be difficult to interpret. (iii) In practice, it is more likely to decide about stratification after 
knowledge of synergy potential. 
 
Synergy Model 1: For functionally similar target pairs (Mechanism 1), we rank the pathways 
based on their sensitive or resistant interaction profile with respect to the drug targets 
(Supplementary Figure 2). We postulate that synergy is maximized under a pathway condition 
where both drugs’ effects are maximized. The optimal condition for synergy is therefore when 
pathways associated with drug sensitivity are upregulated, and pathways associated with drug 
resistance are downregulated. As a consequence, if two protein targets have strong functional 
similarity e.g. high correlation between their interaction profile with pathway activities, synergy is 
maximized by maximizing the sensitizing pathways and minimizing the pathways conferring 
resistance. We predict synergy by taking the average of the N top sensitive pathway scores, 
subtracted by the average of the M top resistant pathway scores. Therefore, for each cell line, 
we introduce the concept of Delta Pathway Activity (Delta PA) to predict synergy: 
 
 𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 =  
∑  𝑁1 (𝑇𝑜𝑝 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑒 𝑝𝑎𝑡ℎ𝑤𝑎𝑦𝑠)
𝑁
 −  
∑  𝑀1 (𝑇𝑜𝑝 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑡 𝑝𝑎𝑡ℎ𝑤𝑎𝑦𝑠)
𝑀
 ± 𝑔𝑒𝑛𝑜𝑚𝑖𝑐𝑠    
 
 We compute the average pathway score for both sensitive and resistant groups. Each group 
should include a minimum of one to a maximum of three pathways. We select the top pathways 
with cross validation of group membership thresholds (Methods). If applicable, we include in the 
formula the genomic information which can be mutation (SNP) or copy number variation (CNV). 
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For instance if protein EGFR is targeted, we include CNVEGFR. Group membership parameters 
are defined using cross validation (Methods). 
 
Synergy Model 2: For functionally opposite target pairs (Mechanism 2), when a pathway’s 
activation is associated with resistance for one protein target, it is also associated with 
sensitivity for the other protein target, to compensate. Two drugs can be individually ineffective, 
but more effective when combined. Therefore, synergy may arise in a situation of drug 
resistance. This could be explained by the fact that if a cell line is resistant for one (or both) of 
the drugs, there is "more opportunities" to be synergistic. When both drugs kill a given cell very 
efficiently, there is no synergy, as both drug A alone, drug B alone and combination A + B can 
kill all the cells. Unsurprisingly, resistance biomarkers were found to be predictive of synergy in 
the recent AstraZeneca DREAM challenge(Menden et al. 2017a). Therefore Delta PA should 
maximize the pathways conferring resistance and minimize the sensitizing pathways. The 
formula becomes: 
 𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 =  
∑  𝑀1 (𝑇𝑜𝑝 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑡 𝑝𝑎𝑡ℎ𝑤𝑎𝑦𝑠)
𝑀
 −  
∑  𝑁1 (𝑇𝑜𝑝 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑒 𝑝𝑎𝑡ℎ𝑤𝑎𝑦𝑠)
𝑁
 ± 𝑔𝑒𝑛𝑜𝑚𝑖𝑐𝑠    
 
 Model 2 is less likely to suit functionally similar pairs (Mechanism 1). If the two drugs have 
similar functional profile, maximizing the resistance scenario equals increasing the dose of the 
same inefficient drug, thus, unlikely to improve the outcome. Likewise, Model 1 is less suitable 
for Mechanism 2, as maximizing the sensitizing pathways is the same as prioritizing a situation 
where drug 1’s sensitive effect outweighs drug 2’s resistant effect. Thus, Mechanism 2’s core 
idea would become obsolete, as by definition, the resistance scenario must prevail in case of 
escape mechanism. Of note, having an opposite functional profile does not imply Mechanism 2. 
An opposite pathway-response profile for 2 targets, offers the “functional scenario” for the cell to 
escape the damage induced by one drug. Yet, there could still be a scenario which maximizes 
the sensitizing pathways. This corresponds to 2 drugs targeting completely independent 
pathways, which is more due to independent actions rather than additivity or synergy(Palmer 
and Sorger 2017). 
 
 Our general framework to predict synergy scores follows several key steps and we emphasize 
on the notion of “target combination” which represents the dual inhibition of two protein targets, 
regardless of the drugs that are used (Methods). 
 
 Motivated by these general trends across all samples, we developed models to predict synergy 
in individual samples. We predicted synergy as a linear combination of pathway activation 
scores and built one model for functionally similar target pairs and one model for opposite pairs. 
We then applied our methodology on AstraZeneca drug combination data for breast tissue and 
experimentally validated a predicted synergistic drug combination for colorectal cancer cell 
lines. 
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Application to the AstraZeneca breast data set (Supplementary text 1) 
 
 We tested our synergy models on different target pairs by computing the Pearson’s correlation 
of observed versus predicted average synergy on all available cell lines. The observed average 
synergy includes all drug combinations targeting the target pair of interest, computed as 
described in the Methods section. Therefore, for each cell line, the observed average synergy 
may be computed for different drug combinations since the matrix of drug-cell line synergy is 
very sparse. 
 
 We selected target pairs that fulfilled the following conditions: 1) Observed CombeneFit 
synergy score(Di Veroli et al. 2016) of top hits must be greater than 20 (Figure 2b), considered 
as a clear threshold for synergy(Menden et al. 2017a). 2) Drug combinations have had to be 
tested in at least 10 cell lines, owing to the limitations of measuring performance by Pearson’s 
correlation. 3) At least two different drug combinations for the target pair were tested in each cell 
line, otherwise we excluded the cell line. We focused on the target pairs rather than specific 
drug pairs, in order to derive more robust insights. 
 
 This leaves us with the following 7 target pairs: AKT/ALK, AKT/MTOR, AKT/PARP1, 
AKT/EGFR, BCL2/MTOR, EGFR/MTOR, and AKT/BCL2, each representing several distinct 
drug combinations (3, 5, 3, 4, 4, 6 and 4, respectively). We applied our methodology on those 
target pairs (Methods, Supplementary text 1), and the prediction performances defined as 
correlations of observed versus predicted synergies are as follow: AKT/ALK (r=0.33), 
AKT/MTOR (r=0.086), AKT/PARP1 (r=0.50), AKT/EGFR (r=0.15), BCL2/MTOR (r=0.20), 
EGFR/MTOR (r=0.43) and AKT/BCL2 (r=0.19) (Table 1, Figure 3), with an average 
performance of 0.27 using Leave One Out Cross Validation (Methods, Table 1). 
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Table 1: Drug synergy prediction for breast and colorectal cancer cell lines. 
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Figure 3: Prediction of drug synergy on breast tissue. (a), (b), (c), (d), (e), (f) and (g) show 
the prediction result for AKT/ALK, AKT/MTOR, AKT/PARP1, AKT/EGFR, BCL2/MTOR, 
EGFR/MTOR and AKT/BCL2 targets pairs on breast tissue, respectively (from AstraZeneca 
DREAM challenge). 
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Literature supporting the drug combinations 
 
AKT/ALK: 
(i) It has been shown that synergy arises by targeting ALK and a downstream signaling pathway 
such as PI3K/AKT/MTOR in neuroblastoma (Moore et al. 2014), but not yet known in breast. 
(ii) MAPK pathway is the top predictive feature of the Delta PA formula (Table 1), and it is 
known that MAPK is a critical downstream pathway necessary for ALK+ tumor cell survival 
(Hrustanovic and Bivona 2015), in agreement with the fact that Model 2 (synergy by maximizing 
resistance) was used as predictive model. 
 
AKT/MTOR: Since AKT and MTOR are from the same pathway, dual targeting of those proteins 
is an obvious choice since breast cancer growth is often dependant on the PI3K/AKT/MTOR 
cascade (Cidado and Park 2012). 
 
AKT/PARP1: PI3K pathway is among the top predictive features in the Delta PA formula (Table 
1). Unsurprisingly, PARP inhibitor and PI3K inhibitor were described as an effective combination 
therapy for breast and ovarian cancer (Condorelli and André 2017; D. Wang et al. 2016; 
Rehman, Lord, and Ashworth 2012). We haven’t found any literature evidence for dual targeting 
of AKT and PARP1 in breast cancer, but the efficacy would not be surprising since PI3K and 
AKT are closely related in the same pathway. 
 
AKT/EGFR: Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR inhibitors in 
triple-negative breast cancer cells (Yi et al. 2013).  
 
BCL2/MTOR: There is a strong synergy between BCL2 and MTOR inhibitors(Hamunyela, 
Serafin, and Akudugu 2017). A cross talk between VEGF and BCL2(Bufalo et al. 2004) and the 
potential of targeting VEGF/MTOR(Chen et al. 2012) could explain that VEGF pathway score 
was the top predictive feature of synergy (Table 1). 
 
EGFR/MTOR: Dual inhibition of EGFR and MTOR has been described for small cell lung 
cancer(Schmid et al. 2010) and for breast cancer (Glaysher et al. 2014). 
AKT/BCL2: AKT regulates BCL2 expression in breast cancer(Bratton et al. 2010) but dual 
targeting of AKT and BCL2 has not been described. 
 Overall, among all target pairs, AKT/EGFR, AKT/MTOR, BCL2/MTOR, EGFR/MTOR and 
AKT/BCL2 were predicted with Model 1 (synergy by similarity). AKT/ALK and AKT/PARP1 were 
predicted using Model 2 (synergy by dissimilarity). 
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1.2.6 Validation on colorectal cancer cell lines 
 
 Within our presented study, we chose to validate our target-pathway interaction metric, synergy 
prediction and synergy stratification workflows in colon cancer. In order to ascertain our 
method’s capability in detecting synergy, we chose a drug combination in the following way: 
 
(i) We focused on drug combination involving protein BRAF which is an important protein in 
colorectal cancer as a mutation can result in uncontrolled, non–EGFR-dependent cellular 
proliferation (Nazemalhosseini Mojarad et al. 2013). About 10% of TCGA patients have this 
mutation for colorectal tissue. 
(ii) From the 101 target combinations involving BRAF, we computed their functional similarities 
with BRAF. Insulin Receptor ranked first with a target functional similarity of 0.8 for BRAF/IR 
pair. We next computed the Delta PA formula and MAPK pathway ranked in the top three 
sensitizing pathways for BRAF/IR. Therefore, we chose BRAF/IR as a candidate for validation. 
We used Dabrafenib as a BRAF inhibitor and BMS−754807 as a selective inhibitor of IR/IGF1R 
(Carboni et al. 2009). 
(iii) We chose the proteins BRAF, IR, and IGF1R as drug targets and used the target pathway 
interaction matrix to derive the Delta PA formula. Hypoxia, p53 and MAPK pathways belong to 
the sensitive group. The top resistant pathways are Trail, VEGF and PI3K. The synergy formula 
for Model 1 is therefore: 
 
𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐵𝑅𝐴𝐹/𝐼𝑅)𝑐𝑜𝑙𝑜𝑛  =  
 𝐻𝑦𝑝𝑜𝑥𝑖𝑎 +  𝑝53 +  𝑀𝐴𝑃𝐾
3
 −  
𝑇𝑟𝑎𝑖𝑙 +  𝑉𝐸𝐺𝐹 +  𝑃𝐼3𝐾
3
 
 
 We validated our methodology on 48 colorectal cancer cell lines from the GDSC panel. 
Synergy score is computed with DeltaXMID (Methods). The Pearson's correlation of observed 
versus predicted synergy score is 0.31 for all 48 cell lines (Methods, Table 1, Figure 4a). We 
further reasoned that inclusion of additional information of top predictive pathway should 
increase the predictive power. In this case, the most predictive pathway is Hypoxia. KRAS 
mutation has been shown to differentially regulate the hypoxic induction of HIF-1α and HIF-2α in 
colon cancer (Kikuchi et al. 2009). Hence, we added kRAS status in the Delta PA formula and 
the prediction performance rose to 0.4 (Figure 4c). The performance rose to 0.5 by including 
BRAF status in the Delta PA formula and by only considering the subset of 26 KRAS mutant cell 
lines (Figure 4d). 
 
 We applied our synergy stratification workflow on breast and colon tissues. As real world use 
case, we envision that for any drug combination described as synergistic, this method could 
potentially inform about the subset of patients most likely to benefit, based on their 
transcriptomics profiles. 
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Figure 4: Prediction of BRAF/IR synergy on colorectal tissue. (a) shows the prediction 
result of BRAF/IR (BMS−754807/Dabrafenib) on all 48 colorectal cancer cell lines. (b) shows 
the result with BRAF status included in Delta PA formula. (c) and (d) show the result on 
KRASmut colorectal cancer cell lines. Drug screens were performed by the Translational 
Cancer Genomics drug screening team of the Wellcome Sanger Institute. 
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1.2.7 Validation of synergy mechanism on external dataset 
 
 We explored the O'Neil et al Merck drug combination dataset(O’Neil et al. 2016) for colon, 
NSCLC lung and ovarian tissues, comprising data for 6, 6, and 5 cell lines, respectively. Given 
the number of samples per tissue, assessment of synergy is not possible on a drug wise setting. 
Nevertheless, we plotted the top synergistic pairs against the target functional similarity 
(Supplementary Figure 4). For colon tissue, the correlation between the average top 
synergistic pairs and the absolute value of target functional similarity is r=0.13 (p=0.11), versus 
r=0.45 (p=0.27) for AstraZeneca (Supplementary Figure 1). For NSCLC lung, there is no 
correlation with r=0.04 (p=0.62), versus r=0.14 (p=0.56) for AstraZeneca (Supplementary 
Figure 1). For ovarian tissue where the correlation is -0.16 (p=0.044), synergy seems to occur 
in case of low correlation between the drug targets. For colon and lung tissues, there is a slight 
agreement between the AstraZeneca and Merck datasets, supporting the methodology based 
on targeting functionally very similar or very opposite proteins. 
 
1.2.8 Comparison with supervised learning approach 
 
 In the AstraZeneca DREAM challenge, an ensemble of best performing models was trained on 
the AstraZeneca DREAM combinatorial data, and consecutively tested on an independent 
combinatorial screen from Merck (O’Neil et al. 2016), which achieved a weighted mean 
correlation of 0.15-0.17. We considered this setting for predicting synergy of new drugs and new 
cell lines (Supplementary Figure 5). In comparison, our synergy stratification workflow uses 
the GDSC panel for hypothesis generation and the AstraZeneca dataset for testing. For the 7 
target pairs (29 drug combinations) from breast tissue and one pair of drug combination 
validated on colorectal cancer cell lines, we were able to reach an average drug-wise correlation 
of 0.27. Of note, the two methods are of very different nature and have very different 
applications. Therefore, prediction performances should not be compared directly. In the 
DREAM challenge, synergy scores of drugs/samples are predicted without any prior knowledge 
of a drug combination leading to synergy or not. In contrast, in our synergy stratification 
workflow, we assume that at least one drugs/samples is synergistic and consecutively predict 
the stratification based on pathway activity and mutational profiles. We highlight the pros and 
cons for each methodology in Supplementary Table 2: 
 
(i) Naive supervised learning approaches are easy to implement, do not require extensive 
domain expertise, and can be used for all possible prediction settings, drug wise and cell line 
wise (Supplementary Figure 5). On the other hand, it requires an extensive set of drug 
combination drug response data as training set. 
(ii)  For our synergy stratification methodology, linear combination of pathway activities is well 
suited for biological interpretation. However, it can only be used in drug wise setting and 
requires significant domain knowledge and literature evidence. 
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1.3 Methods 
1.3.1 Matrix factorization with Macau 
 
 Macau trains a Bayesian model for collaborative filtering by also incorporating side information 
on rows and/or columns to improve the accuracy of the predictions (Simm et al. 2017b) (Figure 
1b). Drug response matrix (IC50) can be predicted using side information from both drugs and 
cell lines. We use protein target as drug side information and transcriptomics/pathway as cell 
line side information. Each side information matrix is then transformed into a matrix of L latent 
dimension by a link matrix. Drug response is then computed by a matrix multiplication of the 2 
latent matrices. Macau employs Gibbs sampling to sample both the latent vectors and the link 
matrix, which connects the side information to the latent vectors. It supports high dimensional 
side information (e.g. millions of features) by using conjugate gradient based noise injection 
sampler. 
 
1.3.2 Drug synergy metrics 
 
 For AstraZeneca dataset, drug effects on cancer cell lines are measured at several 
concentrations for each drug. Therefore, the effect is described by a dose-response surface 
rather than a curve.  The benefit of a drug combination can be partly assessed by the extra 
effect obtained when combining the drugs. Drug combinations are classified as synergistic, 
additive or antagonistic, based on the deviation of the observed drug combination response 
from the expected response. The expected response is quantified with the Loewe additivity 
model (Loewe 1953; Berenbaum 1989; Loewe 1928; Fitzgerald et al. 2006). Loewe additivity 
assumes the two drugs act on a protein through a similar mechanism. Synergy score is 
quantified with Combenefit (Di Veroli et al. 2016). 
 
 “In colorectal cancer we tested the drug combination of BMS-754807 and dabrafenib in 48 
colorectal cancer cell lines.  BMS-754807 (S2807, Selleckchem) was screened at 0.5 μM 
against a 7 point dose response of dabrafenib (S1124, Selleckchem), ranging from 10 nM- 10 
μM. The XMID, which is akin to an IC50, of dabrafenib alone and dabrafenib in combination with 
BMS-754807 were calculated and the  ΔXMID=XMID(dabrafenib)-XMID(dabrafenib+BMS-
754807) calculated. The fold difference in XMID can be calculated by y-fold=2^ΔXMID, hence a 
ΔXMID of 3.32 corresponds to a 10-fold lower XMID for dabrafenib + BMS-754807 compared to 
dabrafenib alone.” (Text written by Patricia Jaaks, Wellcome Sanger institute) 
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1.3.3 General framework for predicting synergy score 
 
Step 1: For two given protein targets T1 and T2, find their interactions with the PROGENy 
pathways using Macau (Supplementary Figure 3).  
 
Step 2A: If available, use literature to guide the choice of Model e.g if we know that a drug 
combination is synergistic when a pathway X is activated, the model would be the one which 
gives a positive sign for pathway X. Otherwise go to Step 2B. 
 
Step 2B: Compute the functional similarity between T1 and T2 (pearson correlation between T1 
and T2’s interactions with the pathways).  
 
- If the correlation is close to 1, use Model 1 to define the Delta PA formula.  
- If the correlation is close to -1, use Model 2 to define the Delta PA formula.  
- If the correlation is between -0.3 and 0.3, it is an undetermined case. 
 
Step 3: Find top sensitive and top resistant pathways (as previously described in synergy 
models). Take into account literature evidence in choice of pathways (for known drugs or 
targets). If a pathway is described as important in literature but does not appear in top 3 of a 
group, we include it, as well as any pathway separating the first from the one of interest, while 
respecting the limit of three pathways per group. 
 
Step 4: In case of multiple drugs representing the same target pair, as in the AstraZeneca data 
set, remove as many drugs as possible to reduce off target effects (at least 3 drug pairs left). An 
alternative is to take the off target into account if some drugs are targeting one of PROGENy 
pathways.  
 
Step 5: Use the Delta PA formula to predict synergy of a drug combination targeting T1 and T2. 
The pathway activities of the formula are computed by PROGENy on the cell lines of interest.  
 
1.3.4 Cross validation of group membership thresholds 
Prediction using a fixed threshold for both groups 
 For computing the Delta Pathway Activity formula, we chose the group membership to be the 
same in the top sensitive and top resistant groups. We only included pathways producing more 
than 70% of the effect of the first selected pathway. This choice of parameter seems to be a 
reasonable choice between including no additional pathway (threshold close to 100%) and 
including too many potentially irrelevant pathways (50%). We did a sensitivity analysis for this 
parameter and used different thresholds for the 2 different groups (sensitive and resistant). We 
fixed one group’s threshold while varying the other group’s threshold. We observe that for many 
target pairs, the sensitive group’s threshold is rather stable (Supplementary Figure 6). For the 
sensitive group, the model is quite robust to variation of this parameter, whereas for the 
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resistant group, a lower threshold (including more pathways) seems to yield better result. This 
could be explained by the fact that GDSC drug screening adjusts the drug concentration so that 
only a few cell lines respond while most are resistants. Therefore, more information are 
reflected from the resistant side than from the sensitive side. 
 
Prediction using cross validated and different thresholds for each group 
 We next predicted each target pairs of AstraZeneca breast data with a Leave One Out Cross 
Validation (LOOCV) to optimize the group membership thresholds. For each target pair, we 
used as thresholds the best values all target pair of the training set. The average prediction of 
the 7 target pairs is 0.27. Finally, we used the average parameters for the breast data to predict 
the BRAF/IR in colon data (Table 1). 
 
 
1.3.5 Data 
 
GDSC data were downloaded from: http://www.cancerrxgene.org/ 
Drug IC50 version 17a 
Basal gene expression 12/06/2013 version 2 
Drug target version March 2017 
 
DREAM drug combination challenge data were acquired through an AstraZeneca Open 
Innovation Proposal. 
 
Merck drug combination data is downloaded from the publication O’Neil et al(O’Neil et al. 2016) 
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1.4 Discussion 
 
 In this project, we presented two workflows for drug synergy prediction and patient stratification.  
The synergy prediction workflow can be a powerful framework for compound prioritization in 
large scale drug screenings. For instance, only testing drugs targeting two functional very 
similar or very opposite proteins (|correlation| > 0.7) could significantly reduce the search space, 
therefore decreasing the cost of drug combination research. The synergy stratification workflow 
could potentially be used to maximize the drug efficacy of drugs already known for inducing 
synergy. Indeed, knowing that a pair of compounds is synergistic does not tell us on whom to 
use it. We modeled the genomic context with linear combination of pathway activities. 
 
 We introduced the notion of functional similarity between two protein targets. This metric shed 
lights on two scenarios where drug synergy occurs: when drugs are targeting functionally similar 
proteins (AKT/EGFR, AKT/MTOR, BCL2/MTOR, EGFR/MTOR and AKT/BCL2) and when they 
are targeting functionally opposite proteins (AKT/ALK and AKT/PARP1). Our results support 
that synergy occurs and is much easier predicted when the targets are functionally very similar 
or very anti similar. Portraying the interaction between protein targets and pathway activities 
allowed us to recognize the different synergy cases. Based on that, we predicted synergies of 7 
target pairs (AKT/ALK, AKT/MTOR, AKT/EGFR, BCL2/MTOR, EGFR/MTOR and AKT/BCL2, for 
29 drug combinations) in breast cancer cell lines. We validated the synergy hypothesis for colon 
and lung tissues in an independent dataset. Finally, we predicted and validated a drug 
combination synergy (Dabrafenib/BMS−754807) on 48 colorectal cancer cell lines. 
 
 There are several limitations to this study that can be the focus of future work: (i) Better synergy 
models are needed, such as one which takes into account non-linear effects of pathways; we 
could envision adding coefficients to each pathway and including AND/OR gates. But this would 
require an extensive training set. (ii) In this present work, target functional similarity is defined 
with respect to 11 PROGENy pathways, which do not necessarily capture all cancer 
mechanisms. Therefore, the need to expand this geneset to include more cancer relevant 
pathways. (iii) In order to predict synergy of new compounds, drug targets have to be profiled by 
large scale monotherapy drug screening experiments across hundreds of cell lines. Thus, the 
need to expand single drug response data, while this is at a complexity cost of O(n), running 
drug combinations are O(n2). 
 
 Our study findings are aligned to those of the DREAM drug combination challenge(Bansal et al. 
2014), where synergy was found to be highly context dependent. In our case, we predicted 
synergy with a linear combination of pathway activities. Bansal et al. predicted synergy from 
single-compound perturbation data e.g. synergy occurs for drug pairs which induce very similar 
or very opposite gene perturbation statuses. We used single-compound drug response data and 
the Macau algorithm to compute the target functional similarity, which reflects the similarity of 
drug response changes for different pathways after targeting a specific protein. We found that in 
breast and colorectal cancer, compounds which have very similar or very opposite functional 
profiles tend to be more synergistic. We used the inferred synergy mechanism and pathway 
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activities to predict synergy of new compounds. We found that whether synergy arises in case 
of similarity or dissimilarity was also tissue specific. Hence adding more complexity in drug 
synergy predictions. 
 
 Palmer et al stated that successful drug combination in tumour shrinkage are mostly due to 
targeting unrelated pathways, without any real synergy(Palmer and Sorger 2017). Drug action 
similarity is defined by the correlation of single drug response data, which resembles our use of 
target - pathway based similarity score. We used synergy and not additivity as response 
variable, thus in line with the lack of real synergy in lowly correlated group both in our analysis 
and as described by Palmer et al. They also concluded that drug interaction (synergy and not 
additivity) can explain the majority of combination clinical trial only if the drugs have strong 
cross-resistance (i.e. highly correlated independent drug responses), whereas low cross-
resistance (i.e. lowly correlated independent drug responses) makes independent action of 
drugs the dominant mechanism in clinical populations. While the assessment of synergy is 
different in our case, as we used cell line data, the overall conclusions are in agreement. 
 
 In summary, exploring the interactions between drug targets and signaling pathways in a tissue 
specific manner can provide a novel in-depth view of cellular mechanisms and drug modes of 
action, which can ultimately rationalize drug combination strategies in cancer. Target functional 
similarity could be used as a metric for compound prioritization. Synergy by similarity hypothesis 
could be a rational for first line treatment, while synergy by opposite effect could potentially fit 
patients having acquired resistance.  
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Chapter 2: Quantitative prediction of proteome for large scale 
proteogenomics characterization of tumor samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 35 
2.1 Introduction 
 
 DNA sequence information is transcribed into mRNA, which is then translated into protein. 
Such process is known as the central dogma of molecular biology, and characterizes a complex 
series of events allowing the flow of genetic information to phenotype. Since proteins are the 
product of mRNA translation, their abundance is likely to correlate with mRNA level. In steady-
state conditions, protein abundances are largely determined by mRNA levels (Liu, Beyer, and 
Aebersold 2016). But during highly dynamic phases, such as cellular differentiation or stress 
response, post-transcriptional modifications (PTM) may weaken the protein/mRNA correlation 
(Liu, Beyer, and Aebersold 2016). This could explain the correlation between protein/mRNA of 
0.36-0.5 for the majority of human tissues (Kosti et al. 2016). 
 
 Characterization and analyses of alterations in the proteome hold the promise to revolutionize 
cancer research, through understanding the association between genome, transcriptome and 
proteome in tumors. Signaling molecules bind to protein receptors, which are the targets of 
many cancer therapies. Therefore, it is essential to characterize them to the best of our abilities. 
For this purpose, we launched a community-based collaborative competition: The NCI-CPTAC 
DREAM Proteogenomics Challenge. The challenge used public and novel proteogenomic data 
generated by the CPTAC to answer fundamental questions about how different levels of 
biological signal relate to one another. In particular, we focused on the following questions: (i) 
Can one predict abundance of any given protein from mRNA and genetic data ? (ii) Can one 
predict phosphoprotein abundances from protein abundance ?  
 
 We explore through machine learning the role of mRNA, potential PTMs, protein regulations 
and degradation (e.g. the effect of other proteins), in predicting protein abundance. PTMs of 
proteins play essential roles in a large number of biological processes. However, technical 
difficulties and high costs of PTMs profiling greatly hamper the abilities of scientists to study and 
understand these important molecules in biological systems. Thus, it is of great interest to 
assess the ability of predicting PTMs activities based on more easily accessible molecular data 
(e.g. mRNA). 
 
 We also construct prediction models for phospho-protein abundances based on global protein 
abundances, RNAseq data and copy number variation (CNV) data from CPTAC breast and 
ovarian studies. Moreover, it is of interest to assess which data type can better predict 
phosphorylation activities and whether an integrative framework could outperform analysis 
based on single-data type. 
 
 As a result of this competition, we used the winning method for downstream analysis of protein 
translation and regulation. We then assessed the utility of of predicted protein abundance using: 
(i) TCGA samples of breast tissue which were not used in the challenge, for survival analysis. 
(ii)  Cancer cell line for drug response prediction.  
 36 
2.2 Results 
2.2.1 Challenge design 
 
 The NCI-CPTAC Proteogenomics DREAM challenge is divided into different subchallenges: (1) 
imputing missing proteomics data (not described in this thesis). (2) The Proteomics 
subchallenge (sc2, led by myself) consists in predicting protein abundance based on mRNA and 
CNA. (3) The Phosphoproteomics subchallenge (sc3, led by Francesca Petralia, Icahn Institute) 
consists in predicting phosphosite abundance based on protein, mRNA and CNA (Figure 1). 
Each subchallenge is composed of multiple rounds: 2 leaderboard rounds, a validation round 
and a collaborative round. To cope with data confidentiality, participants used a docker 
container to store their pre trained models (infrastructure implemented by Thomas Yu, Sage 
Bionetworks). Submission consists of applying the pre trained model to the test data. 
Participants were given a leaderboard dataset to test their model and generate one prediction 
file and one confidence file per leaderboard round. Scores were returned to participants so that 
they can improve their model throughout these rounds for their final round submission which 
was scored against a held-out dataset. In this thesis, we will mainly focus on the Proteomics 
subchallenge. 
2.2.2 Challenge data 
 
 As training data, we used TCGA retrospective collection of 77 breast and 174 ovarian tumor 
samples measured at four biological level along with their measured numbers in breast and 
ovarian tissue: proteomics (10005, 7061), phosphoproteomics (31981, 10057), transcriptomics 
(15107, 15121) and copy number alterations (16884, 11859) (Methods, Figure 1). 
Retrospective proteomics and phosphoproteomics data were downloaded from CPTAC data 
portal and processed by the common data analysis pipeline from CPTAC. For both tissues, 
proteome and phosphoproteome data were acquired using iTRAQ (isobaric Tags for Relative 
and Absolute Quantification) protein quantification methods. As testing data, we used 108 
prospective samples of breast tissue and 82 samples of ovarian tissue, for all four level of 
measurements (Methods, Figure 1). 
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Figure 1: Challenge design and data. For both training and test sets, we have four layers of 
omics data (Copy Number Alteration, mRNA, Proteomics and Phosphoproteomics). CNA and 
mRNA can be used to predict Protein level (Proteomics subchallenge). CNA, mRNA and Protein 
level can be used to predict Phosphosites abundances (Phosphoproteomics subchallenge). 
Data prepared by Zhi Li, New York University. 
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2.2.3 General outcome of the challenge 
 
 A total of 29 teams submitted for Proteomics subchallenge breast. Prediction were evaluated 
based on Pearson’s correlation of observed versus predicted protein abundance across new 
patient samples (Methods, Figure 2). The average prediction performance is r=0.26 (sd=0.17), 
and the best performance r=0.51. For Proteomics subchallenge ovarian, 32 teams submitted, 
with average performance of 0.29 (sd=0.18) and best performance r=0.53. If we consider the 
subset of proteins for which the corresponding mRNA is available, the winning team reached an 
average correlation of 0.55 and 0.53 for ovarian and breast tissues, respectively. The 
improvement are 17% (ovarian) and 15% (breast) compared to the naive correlation between 
mRNA and protein level. 
 
 For Phosphoproteomics subchallenge breast, 16 teams submitted, with average performance 
of r=0.17 (sd=0.16) and best performance r=0.42. For Phosphoproteomics subchallenge 
ovarian, 22 teams submitted, with average performance of r=0.11 (sd=0.11) and best 
performance r=0.33. 
 
Figure 2: Overall performances in the challenges. For each subchallenge, we plot the 
performances of all participating teams in breast and ovarian tissues. The random distribution is 
generated by permutation of protein/phosphoprotein abundances across each patient. Figure 
made by Zhi Li, New York University. 
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2.2.4 Global insights 
 
Data preprocessing and algorithms 
 
 The best performing methods in this challenge were tree and ensemble based. Missing value 
were excluded from predictor variable in training phase. External information such as KEGG 
pathways, Interaction networks, CODON count, GC percentage, protein folding energy and 
transcription factors were also used. Training data were scaled or feature wise standardized. 
The best performing team performed quantile normalization on the training and testing data 
altogether. 
 
 The best performing teams only used mRNA to predict protein abundance for Proteomics 
subchallenge, and found no benefit in including CNA data. For Phosphoproteomics 
subchallenge, protein abundance was the chosen omics layer to predict phosphosite 
abundance. mRNA and CNV were not used as no additional improvement compared to 
proteomics only. 
 
Factors influencing protein prediction performance  
 
 We observed that proteins for which the corresponding mRNA is present were better predicted 
compared to those where it is not measured (Figure 3, p<2.2e-16). Similarly, proteins that are 
“free” were better predicted than those belonging to a protein complex from CORUM database 
(Figure 3, p<2.2e-16). This could be explained by the fact that “free ”proteins are more likely to 
follow the corresponding mRNA level. On the other hand, proteins inside a complex are co-
regulated by other proteins and the structure is more robust to transient variation of mRNA level. 
The best predicted proteins are those which are directly influenced and accessible by mRNA. 
Another factor could be protein size, as complex proteins are bigger, thus mass spectrometry is 
less able to fractionalize the peptides. 
 
 One could hypothesize that more abundant proteins are better predicted, as easily measured 
by mass spectrometry. But we found no evidence of positive correlation between protein 
abundance and predictability. For breast and ovarian tissues, the correlation between prediction 
performance and average abundance across samples are respectively -0.077 (p=7.6e-13) and -
0.25 (p=7.2e-75). The slightly negative correlation could be explained by the fact that proteins in 
complex are generally more abundant than protein out of complex (p<2.2e-16 and p<4.7e-07, 
for ovarian and breast, respectively). 
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Figure 3: Factors influencing predictability. We present for each tissue, the winning team’s 
prediction performance for: (i) all proteins; (ii) subset of proteins for which the corresponding 
mRNA is measured; (iii) subset of proteins for which the corresponding mRNA is missing; (iv) 
subset of proteins belonging to a protein complexe (CORUM); (v) subset of proteins not 
belonging to a protein complexe. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 41 
 We further grouped the genes into HGNC families, then plotted the average prediction 
performance of each family for breast and ovarian (Figure 4).  The prediction performance do 
not vary a lot between breast and ovarian tissues (r=0.88, p=6.4e-33). The best predicted 
families were Aldehyde dehydrogenase, Acyl-CoA synthetase, Integrin alpha subunits and 
Glutathione S-transferase. The least predicted families were histones and ribosomal proteins, in 
both cases functioning as complexes. 
 
 
 
Figure 4: predictability by family of genes. We define the stability of each family as the 
inverse of the coefficient of variation of the predictability across the family. The more stable a 
family is, the less variation in predictive performances across all proteins of the family. 
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2.2.5 Common protein regulators predict survival 
 
 We used the best performing method to explore the feature importance and considered only 
the predictor genes that are top ranked across all proteins. Those genes are likely to be the 
common protein regulators. We took the top 10 regulators with corresponding protein prediction 
performance greater than 0.7, for ovarian: NNMT, SFRP4, FAP, SULF1, MYLK, MCM7, PLS3, 
KRT17, HBB and CILP. And for breast: GBP5, MMP11, DOPEY2, LASP1, CXCL9, ICAM1, 
DENND2D, WDR12, PLCD1 and HOPX. 
 
 We want to assess if the best predicted common regulators can also be predictive of patient 
survival. We chose breast cancer as it has the biggest sample size of patients and used the 
predicted proteomics (901 samples) based on the winning model. After log rank tests of the 10 
predictors after correcting for age, gender, and false discovery rate, proteins PLCD1 and 
WDR12 are the top predictive biomarker of survival with q-values of 0.039 and 0.013, 
respectively. Similarly, we used mRNA of those two proteins for the same survival prediction. 
mRNA PLCD1 and WDR12 have an q-value of 0.079. Protein Phospholipase C Delta 1 
(PLCD1) functions as a tumor suppressor in several types of cancer(Xiang et al. 2010), and it 
comes with no surprise that a higher level of PLCD1 is associated with a better outcome 
(Figure 5). Protein WDR12 is required for maturation of ribosomal protein (Lewinska et al. 
2017), therefore an increase of this protein may result in cell proliferation, thus associated to 
poor clinical outcome. 
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Figure 5: Patient stratification from common regulators. Kaplan Meier plot with proteins 
PLCD1 and WDR12 as the top predictive protein regulators, using predicted proteomics data of 
901 breast cancer samples. 
 
2.2.6 Proteomics insights from patient stratification 
 
 Patient stratification is an important goal in oncology research. However, it is difficult to do any 
survival analysis using real proteomics data due to the small sample size (77 samples for  
breast tissue). Therefore, we applied the winning method to 901 new breast samples from 
TCGA to generate predicted protein abundances from mRNA. Another issue in patient 
stratification is that testing all predictors for survival (log rank test) is highly inefficient, as a 
simple multiple hypothesis correction may invalidate all selected biomarkers. Therefore, we 
used the state of the art Multi Omics Factor Analysis (Argelaguet et al. 2017) to reduce an 
omics dataset into a subset of hidden variables (Factors) that capture the biological/technical 
variability of the dataset (Methods). We applied MOFA on proteomics, mRNA and a 
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combination of proteomics and mRNA. The derived factors were then tested as prognostic 
biomarker of patient survival (Supplementary Table 1). 
 
 We used the top predictive factors to stratify patients. Predicted protein alone identified 2 
predictive factors with respective q values of 0.0014 and 0.00071 of log rank test 
(Supplementary Table 1). One factor was identified from mRNA with comparable q value of 
0.0025 (Supplementary Table 1). Using the combined proteomics and mRNA, we identified 3 
predictive factors with q values of 0.0050, 0.044, 0.0071. 
 
 The top predictive factor of predicted protein is enriched in Peptide chain elongation pathways 
(Supplementary Table 1). Top contributing genes of those factors includes RPL26, RPL29, 
RPL34 and RPL37. A factor analysis on predicted protein abundance was able to identify this 
class of proteins which play an important role in breast cancer (Goudarzi and Lindström 2016; 
Belin et al. 2009; Van Long et al. 2016). Another predictive factor includes TMEM26 and VGLL1 
as to predictive genes. TMEM26 is highly expressed in triple negative breast cancer, and is 
associated with higher risk of recurrence particularly in ERα-negative cases (Mitra 2017; Nass 
et al. 2016). VGLL1 expression is associated with a triple-negative basal-like phenotype in 
breast cancer and correlates with poor survival (Castilla et al. 2014). 
 
 By combining predicted protein with mRNA, we identified the same factor enriched in Peptide 
chain elongation pathway. Another important predictor of survival is Factor 4, with top weighted 
genes in the protein view: ARGLU1, SULT1E1, CEACAM5, AKR1B10 and ING4. And the top 
enriched pathway is Extracellular matrix organization. ARGLU1 has been described as new 
MED1-interacting protein for breast cancer cell growth (Zhang et al. 2011). Genetic 
polymorphisms of SULT1E1 were found to be associated with increased risk and a disease free 
survival of breast cancer (Choi et al. 2005). CEACAM6 plays a role in tumor cell migration, 
invasion and adhesion, and formation of distant metastases (Choi et al. 2005; Blumenthal, 
Hansen, and Goldenberg 2005). AKR1B10 promotes breast cancer metastasis through 
FAK/Src/Rac1 signaling pathway(Huang et al. 2016). ING4 inhibits estrogen receptor activity in 
breast cancer cells (Keenen and Kim 2016). For most of the factors, protein view and mRNA 
view are in agreement for top enriched pathways. 
 
 In overall, predicted proteomics identified more predictive factors than mRNA, with comparable 
predictive performance. It was also able to identify new insights as predictor of survival, which 
were not found using mRNA.  
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2.2.7 Validation on colorectal cancer cell line 
 
 We applied the best performing model (from ovarian) on 47 colorectal cancer cell 
lines(Roumeliotis et al. 2017). The input feature is microarray mRNA and the real proteomics 
data was acquired by isobaric peptide labeling (TMT-10plex) and MS3 quantification. There are 
3039 proteins in common between the DREAM CPTAC predicted and the ones measured in the 
reference paper. The average correlation between the predicted protein and the real protein 
abundance is 0.36 (from -0.37 to 0.88), which is an encouraging result considering that the 
model was: (i) trained on RNAseq and tested on microarray. (ii) trained on proteomics acquired 
using iTRAQ and tested on proteomics acquired by isobaric peptide labeling (TMT-10plex) and 
MS3 quantification.  
 
2.2.8 Application to drug response prediction  
 
 We applied the winning model (from ovarian) to 990 cancer cell lines from the Genomics of 
Drug Sensitivity in Cancer (GDSC) screening(Iorio et al. 2016c). Each cell line is treated by 265 
drugs. We used Elastic net algorithm to predict drug response IC50 (Concentration of Inhibition 
at 50% viability) using 10 fold cross validation, repeated 100 times. The average predictive 
performance for the 265 drugs is 0.41 using mRNA and 0.40 using predicted proteomics. We 
found no significant difference between the two groups in term of performance (p=0.37).  
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2.3 Methods 
2.3.1 Challenge data 
 
 TCGA retrospective collection of breast and ovarian tumor samples quantitatively measured at 
four biological levels (proteomics, phosphoproteomics, transcriptomics (mRNA) and copy 
number alterations (CNA) were used as training data for CPTAC-NCI dream challenge. 
Prospective samples of the same cancer types with all four level measurement was generated 
and used as testing data for performance evaluation. Sample size varies between different 
platforms due to the availability and quality of original tumor samples at the time of the study. 
Mass-Spectrometry based proteomic and phosphoproteomic characterization of these tumor 
samples yield more than hundred of thousand protein and phosphosite identifications combined, 
which will serve as the target to be predicted in the sub-challenges. 
 
Training Data 
  
Breast cancer: 
■ Proteome: 10005 proteins for 105 patients 
■ Phosphoproteome: 31981 phospho-sites for 105 patients 
■ CNA: 16884 genes for 77 patients 
■ mRNA: 15107 genes for 77 patients 
Ovarian cancer: 
■ Proteome from PNNL: 7061 proteins for 84 patients 
■ Proteome from JHU: 7061 proteins for 122 patients 
■ Phosphoproteome: 10057 phosphosites for 69 patients 
■ CNA: 11859 genes for 559 patients 
■ mRNA(Array): 15121 genes for 569 patients 
■ mRNA(RNA-seq): 15121 genes for 294 patients 
  
 Training proteomics and phosphoproteomics data of breast and ovarian tumors were 
downloaded from CPTAC data portal and processed by the common data analysis pipeline from 
CPTAC. For both tissues, global proteome and phosphoproteome data were acquired using 
iTRAQ (isobaric Tags for Relative and Absolute Quantification) protein quantification methods 
as described previously. For breast proteome, 105 (77 passed QC) tumors from different 
patients were analyzed at the Broad Institute. The protein log ratios of the protein abundance 
were calculated including only peptides that map unambiguously to the protein. Breast tumor 
samples ('TCGA-AO-A12B', 'TCGA-AO-A12D', 'TCGA-C8-A131' assayed in duplicate for quality 
control purposes) were mean aggregated in the uploaded training data (https://cptac-data-
portal.georgetown.edu/cptac/s/S015). For ovarian proteome, there are 206 samples from 174 
unique patients (84 from Pacific Northwest National Laboratory (PNNL), 122 from Johns 
Hopkins University and 32 measured by both centers). We provided participants with both 
proteome collections for training to cover the maximum number of samples for Proteomics 
subchallenge.  
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 CNA data were directly downloaded from two CPTAC publications. Non unique gene IDs were 
median aggregated. Transcriptomics data for both cancer types were downloaded from TCGA 
firehose. RNA-seq (RSEM z-score, median aggregated) were chosen for breast cancer. 
Microarray data and RNA-seq data were both downloaded for participants to use for ovarian 
cancer. The main reasons of providing participants with both datasets are sample coverage is 
greater between microarray and proteome, however only RNA-seq was performed for 
prospective collection. 
 
 
Testing Data 
 
CNA, RNA-seq, Proteome from prospectively collected patients were provided as testing data.  
  
First and second round: 
Ovarian cancer: 
■ Proteome: 7061 proteins for 20 patients 
■ Phosphoproteome: 10057 phosphosites for 20 patients 
■ CNA: 11859 genes for 20 patients 
■ mRNA(RNA-seq): 15121 genes for 20 patients 
Final round: 
Breast cancer: 
■ Proteome: 10005 proteins for 108 patients 
■ Phosphoproteome: 31981 phospho-sites for 108 patients 
■ CNA: 16884 genes for 108 patients 
■ mRNA: 15107 genes for 108 patients 
Ovarian cancer: 
■ Proteome: 7061 proteins for 62 patients 
■ Phosphoproteome: 10057 phosphosites for 62 patients 
■ CNA: 11859 genes for 62 patients 
■ mRNA(RNA-seq): 15121 genes for 62 patients 
 
The training data has been prepared by both Zhi Li (New York University) and I. The testing 
data has been exclusively prepared by Zhi Li. 
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2.3.2 Scoring 
 
Proteomics subchallenge: prediction of protein abundance based on mRNA 
 
 These models are evaluated in two novel, unpublished held-out datasets: ovarian and breast 
tissue. We will only focus on 5220 proteins for ovarian and 8649 proteins for breast with less 
than 30% missing values in both training and testing data. We first compute the pearson 
correlation between observed and predicted abundances across all samples for each protein. 
We then take the mean correlations of proteins in the test data set as the final evaluation score. 
If there is a tie, we will further use NRMSE for all proteins to select the winner. 
  
 
Phosphoproteomics subchallenge: prediction of phosphosites abundance based on protein 
abundance 
 
 We will only focus on 1318 phosphosites for ovarian and 4907 phosphosites for breast with less 
than 30% missing values in both training and testing data. We first compute the pearson 
correlation between observed and predicted phosphosite abundances across all samples for 
each phosphoprotein. We then take the mean correlations of phosphoproteins in the test data 
set as the final evaluation score. If there is a tie, we will further use NRMSE for all 
phosphoproteins to select the winner. 
  
 
2.3.3 Winning method 
 
 The winning team (Hongyang Li, Yuanfang Guan, University of Michigan) used a weighted 
average of four major models for prediction (Figure 6): 
 
Protein proxy model: This model is based on the observations that protein and transcript levels 
are correlated, and simply uses the transcript level of a given gene as a proxy for its protein 
level. Missing values positions are replaced with the gene average across non-missing samples. 
This model has several limitations including that it assumes no differential translational 
regulation and degradation, and it disregards interaction between genes. 
 
Interaction model: Since different genes are regulated differently, individual models were built 
for each gene using random forests with maximum depth of 5 and 100 trees. The response 
variables for training are the non-missing observations across all samples, and as features the 
values for all genes as training features to take into account gene interactions. 
 
Pan-cancer model: The performance of individual model is limited by the sample size. The 
training data only contain 77 and 174 tumors for breast and ovarian, respectively. This is a 
relatively small sample size, but when combining all the samples, a better performance was 
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achieved as the majority of genes have similar regulation across different tissues (Wang, 
Zhang, and Du 2013). 
 
 For the phosphorylation prediction task, the proxy model was changes to use protein levels 
instead of transcript levels and a fourth model was added: 
 
Phosphorylation proxy model: This model is based on the observations that protein and 
phosphorylation levels are correlated albeit only modestly, and simply uses the protein level of a 
given gene as a proxy for its phosphorylation level. This model assumes that for any given gene 
a constant fraction of the proteins are phosphorylated. 
 
Phosphosite correlation model: The levels of multiple phosphorylation sites from the same 
protein are not independent. The biological rationale behind this model is that if a protein is 
phosphorylated, it is likely that multiple phosphosites are phosphorylated co-regulated. In 
addition, for technical limitations it is sometimes not possible to distinguish two phosphosites 
that are very close in the linear sequence so that they are in the same peptide after digestion 
and no fragment peaks are observed from fragmentation between them. Therefore, a 
phosphorylation site is correlated with other phosphorylation sites on the same protein, the 
winning team utilized this and calculated the weighted average prediction from all 
phosphorylation sites of the same gene as the multi-site prediction. 
 
2.3.4 Ensemble method from top performers 
 
 We next sought to further improve the prediction by the organizing a collaboration round 
between the top 4 ranked teams (led by Francesca Petralia, Icahn Institute). Each team has for 
objectives to improve their own methods and to incorporate other teams’ specificities (Figure 6).  
 
 Team hyu used Random Forest algorithm and mRNA as proxy. mRNA features were filtered 
based on KEGG signaling pathway and human PPI network information, as well as their 
correlation with the responses. When applicable, all neighbors within a distance of 2 from a 
protein, in either KEGG pathway or PPI network, were selected. This set is then expanded by all 
genes belonging to pathways of mRNA surveillance, RNA degradation, RNA polymerase, basal 
transcription factors, cell cycle, protein processing in endoplasmic reticulum and microRNAs in 
cancer, because these pathways are assumed to play important roles in regulating translation. 
 
 Team DEARGENpg predicted protein and phosphoprotein abundances, by grouping genes 
into signalling pathways, selected 300 Protein, CNA, mRNA features using Pearson correlation 
scores and an ensemble model of XGboost, Extra Tree and Random Forest, using stacking. 
PAM50 breast subtypes (basal-like&HER2 and LuminalA&LuminalB) have been added to each 
patient (0 or 1) using PCA in 2 dimensions and then K-means clustering. Gene meta information 
were added considering Codon count, GC count and Folding energy. 
 
 Team DMIS_PTG trained models for each protein using LASSO regression. Features were 
selected based on PPI networks (BioGRID, BTNET and CORUM) and biological pathways. The 
genes which are 1-hop from the target protein gene in the union network explained above. The 
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average of the number of these features for all protein models is approximately 20. Gene sets 
were selected using MSigDB where all the component genes are included in the training gene 
expression data. Then, a median value of the expression value for each gene set were used as 
feature. Around 700 median values of gene sets were included. Both microarray and RNAseq 
data were used for training. Although the testing data only provides RNAseq, microarray training 
data contain more sample than RNAseq.  
 
 “To improve the prediction performance, we assembled the models of the top 4 teams from the 
challenge. By analysing the 5-fold cross validation results of these models on the training data, 
the prediction correlation of each protein was calculated. For each protein, the correlation 
scores were used as the stacking weights of these top 4 models (hereafter referred to as the 
individual ensemble model). To estimate the overall performance, the average correlation of all 
proteins was calculated and used as the weights for all proteins (hereafter referred to as the 
global ensemble model). For the ovarian cancer, we observed a significant improvement 
(0.5605) of the global ensemble model, compared with the best performer in the challenge final 
round (0.5284), p<2.2e-16. However, the improvement of the global ensemble model is very 
marginal in breast cancer, only from 0.5052 to 0.5063, p=1. We further calculated the 
normalized root mean square error (NRMSE) of these model and found that the global 
ensemble model reduced the error from 0.1863 to 0.1750 in the ovarian cancer. Similar 
correlation scores were observed for predictions of the individual ensemble model in both breast 
and ovarian cancers.” (Analysis performed and text written by Hongyang Li, University of 
Michigan) 
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Figure 6: Prediction models of the best performers. 
 
The input data are on the left (mRNA, DNA, proteomics) and the prediction output are on the 
right (Proteomics and Phosphoproteomics subchallenges). Each team starts with the input data 
on the left and navigates to the right side, the stations they crossed representing the methods 
they used. 
 
Paths taken by each team for the Proteomics Subchallenge: 
1) Team Hongyang Li and Yuanfang Guan used Protein proxy model, Random forest and Pan 
cancer model.  
2) Team Hyu used Random forest. Features were selected by KEGG pathway and PPI (Human 
Protein Reference Database).  
3) Team DEARGENpg built models on a groups of proteins, used ensemble of Random 
Forest+XGboost+Gradient Boost, and additional features such as gene metadata (codon bias, 
GC count and folding energy of each protein). 
4) Team DMIS_PTG used LASSO. Features were selected based on Gene Regulatory 
Network, CORUM protein complexes, PPI, and LASSO.  
 
Paths taken by each team for the Phosphoproteomics Subchallenge:  
 
1) Team Hongyang Li and Yuanfang Guan used Phosphoprotein proxy model, Random forest, 
Pan cancer model and Phosphoprotein correlation model.  
2) Team Ardigen used Phosphoprotein proxy model and used algorithm LARS. 
 
Figure made by Nicolàs Palacio and designed by both of us. 
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2.3.5 Multi Omics Factor Analysis 
 
 
 MOFA is a statistical model which can identify the principal sources of variation in multi omics 
datasets (Argelaguet et al. 2017). It infers a set of hidden variables (Factors) that capture the 
biological/technical variability of the dataset. MOFA takes an arbitrary number of data matrices 
(omics layers)  (Y1,..., YM) with co-occurrent samples but possibly differing number of features. 
MOFA decomposes these matrices into a matrix of factors, Z, for each sample and M weight 
matrices, one for each view (loadings W1,.., WM). MOFA approximates the true posterior using a 
variational distribution in a factorized form, which is optimized by minimizing the lower bound of 
the marginal likelihood (also called evidence lower bound, ELBO). Unlike the standard principal 
component analysis, each Factor can be defined by several layers of information (proteomics 
AND/OR mRNA AND/OR mutation...etc). Kernel and graph based methods also allow to 
combine multiple omics data, but those approaches suffer from the lack interpretability. Our 
motivation for using MOFA is the panoply of downstream analysis to biologically define a factor 
of interest and associate it with clinical phenotype (such as patient survival). In addition to that, 
MOFA is highly scalable and handle missing values and non-gaussian omics layers (such as 
mutation data). Gaussian distribution was used to model protein and mRNA’s likelihood. For 
binary mutation, we used Bernoulli. We iterated until convergence. 
 
2.4 Discussion 
 
 The winning method of this competition is an ensemble of four models, which consist in: (i) 
Using input feature as proxy of the response variable (Generic model). (ii) Modeling each 
protein based on mRNA expression of other genes, with Random Forest. (iii) Including another 
tissue in training phase (Trans-tissue model). (iv) Modeling phosphosite abundance based on 
the biology and the mass spectrometry technology. 
 
 Unsurprisingly, proteins were better predicted when the corresponding mRNA is available. 
Proteins outside a protein complex were also better predicted than those belonging to a 
complex. The best predicted families were Aldehyde dehydrogenase, Acyl-CoA synthetase, 
Integrin alpha subunits and Glutathione S-transferase. The least predicted families were 
histones and ribosomal proteins. Analysis of commonly protein regulators revealed key proteins 
predictive of patient survival e.g. WDR12 and PLCD1. 
 
 We then assessed the utility of the predicted proteins using: (i) TCGA samples of breast tissue 
which were not used in the challenge for survival analysis and (ii) Cancer cell line for drug 
response prediction. 
 
 We used Multi Omics factor Analysis to reduce the proteomics/mRNA dimension and used 
breast tissue to assess the predicted proteomics’ performance in patient stratification. Predicted 
protein’s performance is comparable to mRNA, and revealed more predictive biomarker. 
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Predicted proteomics identified L ribosomal proteins contributing to patient stratification, which 
were not found using mRNA. Another group of proteins identified by combining proteomics and 
mRNA, were ARGLU1, SULT1E1, CEACAM5, AKR1B10 and ING4, many of them involved in 
cell migration and Extracellular matrix organization. Those results suggest the use of predicted 
protein abundance to explore biological insights under a new angle. 
 
 We applied the winning model to predict protein level on 48 colorectal cancer cell lines from the 
GDSC screening, and reached an average correlation of 0.36 between predicted protein level 
and real protein level, despite the difference of technology used in training and testing. Drug 
response prediction based on predicted proteomics is comparable to using mRNA, which is 
encouraging considering that the model was built on mRNA. These results suggest the potential 
use of predicted proteomics to facilitate drug mode of action elucidation and improve therapeutic 
decisions. 
 
 Regarding prediction of protein level based on mRNA, Wilhelm et al. reported correlations of 
approximately 0.9 between observed versus predicted protein levels (Wilhelm et al. 2014) and 
concluded that protein abundance can be predicted with good accuracy from the corresponding 
gene’s mRNA levels. Fortelny et al. replied that the model was built within genes, whereas the 
assessment of performance was done across genes (Fortelny et al. 2017). This is due to a  
discrepancy between model building and model assessment. The reported performance score 
is not generalizable to new experiments.  
 Cancer drugs are mostly targeting proteins. Therefore, protein targets with low/anti correlated 
protein/mRNA could lead to therapeutic mistakes. If the measured protein abundance reflects 
better the biology, then using mRNA to make clinical decision would be a mistake. On the other 
hand, if mRNA reflects the biology better than the measured proteomics, this could point to 
potential directions of improvement of the mass spectrometry technology or data processing. To 
determine which situation prevails, domain specific gold standards are needed.  
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General conclusions and outlook 
 
 We presented in this thesis different applications of machine learning in knowledge discovery 
for systems pharmacology and cancer biology. We mined the largest public available databases 
of cancer drug screenings (GDSC, CTRPv2 and CCLE), and drug combination data from 
AstraZeneca and Merck. We then worked with the largest primary tumor databases: TCGA for 
mRNA and CPTAC for proteomics. Mining public available databases has several advantages 
over generating your own data: (i) The sample size for a given omics layer is much bigger, thus 
allowing more exploration, discovery, stronger statistical power and use of more sophisticated 
algorithms. (ii) The overlapping samples between different omics layers is also bigger, allowing 
more exploration of the underlying associations between omics layers. We argue that 
biomedical scientists should always start with an initial step of data driven hypothesis generation 
or confirmation, and then experimentally validate the hypothesis. This could significantly 
increase the success rate and better allocation of research time and fund. 
 
 Multitask learning and matrix factorization have been successfully applied to preclinical drug 
response prediction on cancer cell lines. Since the response data is in a matrix format (cell lines 
treated by drugs), this class of algorithm can easily capture the underlying associations between 
the descriptors of the cell lines and the descriptors of the drugs. Such association is on a deeper 
level than a simple drug-gene association, and could potentially be applied to target discovery, 
drug repurposing and patient stratification. 
 
 Machine learning has been widely used for prediction purpose. In the drug combination project, 
we used Macau, a multitask learning algorithm, in a unsupervised way for hypothesis 
generation. Based on the generated hypothesis, we built specific models for prediction. We 
applied this workflow to drug synergy discovery and prediction. This method could: (i) Predict 
whether a pair of compounds could be synergistic for a given tissue, therefore used as a 
compound prioritization framework. (ii) Predict synergy of new drug combinations on new cell 
lines, without performing any experiments. 
 
 In this last project, we explored through a collaborative machine learning competition, the 
relations between protein level and mRNA expression. The best performing algorithm can 
accurately predict protein level on tumor samples from mRNA. Since cancer drugs mostly target 
proteins, the possibility to explore the protein level of tumor samples, could potentially reveal 
new facets of cancer biology. 
 
 In this thesis, we successfully applied machine learning to preclinical drug development and 
cancer biology in real patient tumors. Due to the availability of data, matrix factorization is 
especially suited for in vitro drug screenings. 3D Tensor factorization could also be used, 
provided the availability of a third mode, which could be drug concentration or treatment by an 
additional drug (combination). In clinical scenario, such class of algorithm is unlikely to be 
applied for response prediction (patient survival or drug response), as this would require treating 
the same patient with hundreds of drugs. Therefore, the most commonly used algorithm for 
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clinical data are single task Cox regression, linear regression and Random Forest. 
Nevertheless, Tensor factorization and Factor Analysis could be applied to reduce the 
dimensions of multi omics data (Transcriptomics, Proteomics, Metabolomics...etc). The resulting 
Factors or latent matrix could be used as input features for prediction purpose.  
 
 Cancer drug screenings most often only focus on drugs targeting intracellular processes of the 
cancer cells (Dry, Yang, and Saez-Rodriguez 2016b). It is essential to also consider primary 
tumors and other systems, as cancer cell lines, although the best existing model to study drugs’ 
mode of action, do not take into consideration the immune system nor the 3D structure of the in 
vivo tumor. In the future, ex vivo tumor culture (such as organoids and patient-derived 
xenografts) could be used to reproduce the drug response matrix as in preclinical drug 
screenings. Organoids could mimic in vivo architecture of the tumor within an organ (Dutta, Heo, 
and Clevers 2017), therefore more realistic than in vitro cell line experiments. Patient-derived 
xenografts are immunodeficient mice implanted with patients’ tumors and are currently the best 
in vivo system beside the patient (Lai et al. 2017).  
 
 Clinical trial data and electronic health record are likely to play an important role in precision 
medicine. However, clinical trial data are difficult to obtain and electronic health record could be 
sparse and noisy. Biosensors and smart wearables are promising ways for real-time monitoring 
of patient response, health, and adverse events (Dry, Yang, and Saez-Rodriguez 2016b; 
Cleeland et al. 2012). Such technologies are more efficient in collecting data than from a 
hospital (expensive and slow). 
 Big data approaches could significantly improve the drug development process, decrease the 
cost of making a new drug, and potentially reducing the need for animal experiments. However, 
such perspectives are often perceived as risky by the pharmaceutical industry which most often 
prefers to do what has always been done. In this context of drug development attrition, industry-
academia collaborations are evermore needed. 
 In this thesis, we extensively used machine learning for cancer bioinformatics, from preclinical 
drug screenings to patient outcome prediction. We hope that those results could be used for 
new drug developments, repositioning of old drugs, synergy and biomarker discovery.  
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A   Supplementary information to chapter 1 
A.1 Supplementary text 1: Methodology applied to breast tissue 
 
 We explained through target-pathway interactions, two mechanisms of drug synergy. In order 
to validate our synergy models, we first looked at public data, using the DREAM AstraZeneca 
drug combination challenge(Menden et al. 2017a), which experimentally tested >120 folds drug 
combinations compared to the previous Bansal et al. challenge. Furthermore, the AstraZeneca 
challenge expanded the number of tested cell lines including their deep molecular 
characterisation enabling for the first time identification of synergy biomarkers. We tested our 
model on 7 target pairs (29 drug combinations) from the AstraZeneca DREAM 
challenge(Menden et al. 2017a), and chose breast as the most represented tissue with 33 cell 
lines.  
 
 We applied our general framework to predict synergy scores. The first step was to determine 
the top sensitive and top resistant pathways for a certain target - pathway pair (Supplementary 
Figure 3). We then derived the formula of Delta Pathway Activity and predicted the drug 
synergy (Table 1). When choosing between Model 1 and 2 for the synergy model, the target 
functional similarity was the main criteria. If the similarity is close to 1, we use Model 1. If the 
similarity is close to -1, we use Model 2. 
 
 PI3K/AKT/MTOR pathway plays a significant role in treatment resistance in breast 
cancer(Paplomata and O’Regan 2014). Therefore, we hypothesized that the PI3K pathway will 
be informative of the synergy if AKT is targeted. Therefore, each time AKT is targeted, we 
included PI3K pathway as well as any pathway between the first one and PI3K, while respecting 
the limit of maximum 3 pathways per group. 
 
 When grouping pathways in the top sensitive and top resistant groups, we consider only those 
that have at least one significant interaction with the drug targets. If not significant, we discard 
the pathway. Exceptions are made when only one pathway is included (the top sensitive or top 
resistant one) and when the pathway has a stronger interaction than a pathway included by 
prior knowledge (literature). 
 
 For AKT/ALK (Supplementary Figure 3a, Figure 3a): the top sensitive pathway is EGFR and 
the top resistant pathways are MAPK and TNFa. The target functional similarity between 
AKT1/2 and ALK is -0.4 (Table 1). Therefore, we used synergy Model 2:  
 
 𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐴𝐾𝑇/𝐴𝐿𝐾)𝑏𝑟𝑒𝑎𝑠𝑡  =  
𝑀𝐴𝑃𝐾 +  𝑇𝑁𝐹𝑎
2
 −  
𝐸𝐺𝐹𝑅 +  𝑉𝐸𝐺𝐹 + 𝑃𝐼3𝐾
3
 
 
 For AKT/MTOR (Supplementary Figure 3b, Figure 3b): the top sensitive pathways are EGFR 
and VEGF. The top resistant pathways are MAPK and TNFa. The target functional similarity 
between AKT1/2 and MTOR is 0.8 (Table 1). Therefore, we used synergy Model 1:  
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 𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐴𝐾𝑇/𝑀𝑇𝑂𝑅)𝑏𝑟𝑒𝑎𝑠𝑡  =  
𝐸𝐺𝐹𝑅 +  𝑉𝐸𝐺𝐹 +  𝑃𝐼3𝐾
3
−
𝑀𝐴𝑃𝐾 +  𝑇𝑁𝐹𝑎
2
 
 
 
 
 For AKT/PARP1 (Supplementary Figure 3c, Figure 3c): the top sensitive pathway is EGFR 
and the top resistant pathways are MAPK and TNFa. The correlation between AKT1/2 and 
PARP1 is -0.8 (Table 1). In this case, we used Model 2:  
 
 𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐴𝐾𝑇/𝑃𝐴𝑅𝑃1)𝑏𝑟𝑒𝑎𝑠𝑡  =   
𝑀𝐴𝑃𝐾 + 𝑇𝑁𝐹𝑎
2
 −  
𝐸𝐺𝐹𝑅 + 𝑉𝐸𝐺𝐹 +  𝑃𝐼3𝐾
3
 
 
 For AKT/EGFR (Supplementary Figure 3d, Figure 3d): the top sensitive pathway is EGFR 
and the top resistant are MAPK. The target functional similarity between AKT1/2 and EGFR is 
0.9 (Table 1). Therefore, we used synergy Model 1. Since protein EGFR is targeted, we also 
added CNV information: 
 
𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐴𝐾𝑇/𝐸𝐺𝐹𝑅)𝑏𝑟𝑒𝑎𝑠𝑡  =   
𝐸𝐺𝐹𝑅 +  𝑁𝐹𝑘𝐵 +  𝑃𝐼3𝐾
3
− 𝑀𝐴𝑃𝐾 + 𝐶𝑁𝑉𝐸𝐺𝐹𝑅 
 
 For BCL2/MTOR (Supplementary Figure 3e, Figure 3e): the top sensitive pathways are 
VEGF, NFkB and Trail and the top resistant pathways are MAPK and TNFa. The target 
functional similarity between BCL2 and MTOR is 0.7 (Table 1). Therefore, we used synergy 
Model 1: 
 
𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐵𝐶𝐿2/𝑀𝑇𝑂𝑅)𝑏𝑟𝑒𝑎𝑠𝑡  =   
𝑉𝐸𝐺𝐹 +  𝑁𝐹𝑘𝐵 + 𝑇𝑟𝑎𝑖𝑙
3
+
𝑀𝐴𝑃𝐾 +  𝑇𝑁𝐹𝑎
2
 
 
 For EGFR/MTOR (Supplementary Figure 3f, Figure 3f): the top sensitive pathways are 
EGFR and NFkB. The top resistant are MAPK and TNFa. The target functional similarity 
between EGFR and MTOR is 0.6 (Table 1). Therefore, we used synergy Model 1. Since protein 
EGFR is targeted, we also added CNV information: 
 
𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐸𝐺𝐹𝑅/𝑀𝑇𝑂𝑅)𝑏𝑟𝑒𝑎𝑠𝑡  =   
𝐸𝐺𝐹𝑅 +  𝑁𝐹𝑘𝐵
2
−
𝑀𝐴𝑃𝐾 +  𝑇𝑁𝐹𝑎
2
+ 𝐶𝑁𝑉𝐸𝐺𝐹𝑅 
 
 For AKT/BCL2 (Supplementary Figure 3g, Figure 3g): the top sensitive pathway is EGFR 
and the top resistant pathway is MAPK. The correlation between AKT1/2 and BCL2 is 0.5 
(Table 1). In this case, we used Model 1: 
 
 𝐷𝑒𝑙𝑡𝑎 𝑃𝐴 (𝐴𝐾𝑇/𝐵𝐶𝐿2)𝑏𝑟𝑒𝑎𝑠𝑡  =  
𝐸𝐺𝐹𝑅 +  𝑉𝐸𝐺𝐹 + 𝑃𝐼3𝐾
3
 −  𝑀𝐴𝑃𝐾 
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A.2 Supplementary tables 
 
  
Setting 1 
predicting new 
cell lines 
Setting 2 
predicting new 
drugs 
Setting 3 
predicting existing 
drugs on existing 
cell lines 
Setting 4 
predicting new drugs 
on new cell lines 
 
 
 
use case 
- Personalized 
medicine 
- Drug 
repositioning 
- prioritization for 
new experiments 
- Interaction matrix 
generation 
- Personalized 
medicine with 
previously untested 
drugs 
- Quality control of 
the interaction matrix 
drug 
features 
optional required optional required 
cell line 
features 
required optional optional required 
cross 
validation 
 
10 fold CV 10 fold CV NA 2 x 10 fold CV 
 
 
 
prediction 
metrics 
For each drug, 
correlation of 
observed versus 
predicted IC50 
across all cell 
lines. 
For each cell line, 
correlation of 
observed versus 
predicted IC50 
across all drugs. 
correlation of 
observed versus 
predicted IC50 for 
all drug-cell line 
pairs. 
correlation of 
observed versus 
predicted IC50 for all 
drug-cell line pairs. 
Supplementary Table 1: Different settings for drug response prediction 
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  Supervised learning Hypothesis driven synergy 
stratification 
Data source Drug combination drug response 
on cancer cell lines 
Single agent drug response on 
cancer cell lines 
Input features Gene expression and drug target Gene expression and drug target  
Additional information mutation, CNV, cancer subtypes mutation, CNV, cancer subtypes 
 
Synergy prediction 
algorithm 
Supervised learning algorithms 
such as tree based algorithms 
(Random Forest, XGBOOST) and 
matrix factorization. 
Linear combination of gene 
expression derived pathway scores 
(from PROGENy) 
 
 
 
Prediction settings 
(Supplementary Figure 5, 
Supplementary Table 1) 
Setting 1: prediction of new cell 
lines for existing drugs 
Setting 2: prediction of new drugs 
for existing cell lines 
Setting 3: prediction of existing 
drugs for existing cell lines 
Setting 4: prediction of new drugs 
on new cell lines 
Setting 1: prediction of new cell 
lines for existing drugs 
 
 
 
 
Setting 4: prediction of new drugs 
on new cell lines 
 
 
 
Strength 
(1) General purpose usage in drug 
wise and cell line wise settings 
(2) Does not require domain 
expertise 
(3) Easy to implement 
(1) Does not require many drug 
combination experiments as prior 
knowledge 
(2) Linear combination of pathway 
activation is suited for biological 
interpretation 
 
 
Weakness 
Requires an extensive set of drug 
combination drug response data 
 
(1) Relies heavily on domain 
knowledge and literature evidence, 
making automated processing 
challenging 
(2) Can only be used in a drug wise 
setting 
Supplementary Table 2: Comparison of synergy stratification workflow with supervised 
learning. 
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Supplementary Table 3: drug target information downloaded from 
https://www.cancerrxgene.org on March 2017. 
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A.3 Supplementary figures 
 
Supplementary Figure 1: Influence of target functional similarity in drug synergy for 
AstraZeneca DREAM dataset. The target functional similarity is the correlation between 
two protein targets by their interactions with the PROGENy pathways. For each tissue, we 
plot the synergy against the target functional similarity and its absolute value. (a) and (b) for 
breast tissue. (c) and (d) for colon tissue. (e) and (f) for NSCLC lung tissue. 
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Supplementary Figure 2: Interpretation of the interaction matrix. Enhanced sensitivity 
occurs when targeting several proteins involved in drug response under the activation of the 
right pathway. The same rule applies to resistance. 
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Supplementary Figure 3: Functional profile of protein targets in breast and colorectal 
tissues. (a), (b), (c), (d), (e), (f) and (g) describe the functional profile of AKT/ALK, AKT/MTOR, 
AKT/PARP1, AKT/EGFR, BCL2/MTOR, EGFR/MTOR and AKT/BCL2 pairs in breast tissue. (h) 
describes BRAF/IR’s functional profile in colorectal tissue. The functional profile is a subset of 
the target pathway interaction in the Macau model. Pathways are ordered from the most 
sensitizing to the least. Significance of the interaction values is corrected according to Benjamini 
& Yekutieli procedure (20% FDR) as described in Yang et al. (Yang et al. 2018c). 
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Supplementary Figure 4: Influence of target functional similarity in drug synergy for 
O'Neil et al Merck dataset. The target functional similarity is the correlation between two 
protein targets by their interactions with the PROGENy pathways. For each tissue, we plot the 
synergy against the target functional similarity and its absolute value. Only tissues with at least 
5 cell lines were chosen. (a) and (b) for colon tissue. (c) and (d) for NSCLC lung tissue. (e) and 
(f) for ovary tissue. 
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Supplementary Figure 5: Different settings in drug synergy prediction. (a) Predicting new 
cell lines for existing drugs. For each drug pair, we compute the pearson correlation of observed 
versus predicted synergy across all cell lines of the test set. (b) Predicting new drug synergy for 
existing cell lines. For each cell line we compute the pearson correlation of observed versus 
predicted synergy across all drug pairs of the test set. (c) Predicting existing drug synergy for 
existing cell lines. This is a missing value imputation setting where side information of drug and 
cell lines are not required, but can be used to improve the result. The test data is defined by a 
percentage of the whole data set. We compute the pearson correlation of observed versus 
predicted synergy for all randomly chosen drugs - cell line triplets of the test set. (d) Predicting 
new drug synergy for new cell lines. We do 2 simultaneous cross validation on both drug and 
cell line sides. The test data is defined by association of the test set of the drug side with the 
test set of the cell lines side. We compute the pearson correlation of observed versus predicted 
synergy for all drug - cell line pairs of the test set. 
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Supplementary Figure 6: Sensitivity analysis for group membership parameters. In the 
determination of Delta Pathway Equation, we explored the prediction performance for each 
target pair in AstraZeneca breast data and colorectal validation data, based on the following 
parameters: threshold for group membership of the top sensitive pathways and top resistant 
pathways. 
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Supplementary Figure 7: Distribution of similarity values across tissues. For each tissue, 
we plotted the target functional similarities of the profiled protein targets and set the cut off of 
high similarity and high dissimilarity at 0.7 and -0.7. 
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B   Supplementary information to chapter 2 
B.1 Supplementary analysis 1: MOFA, Robustness assessment 
 
  As we use MOFA factor as prognostic biomarker, one essential condition is to be able to 
recover the relevant factor in a new dataset.  We ran MOFA in a multi omics setting (predicted 
protein + mRNA + mutation) on the breast dataset with 2 fold cross validation, with 1000 MOFA 
iterations, repeated 50 times.  At each run, we identified the most predictive Factor on the 
training set, using log rank test on binarized Factor after correcting for age, and gender, then 
false discovery rate. We then retrieved the corresponding Factor on the test set using 
correlation of the weights, as a factor’s weights is really what defines it. The average absolute 
correlation between the training Factor weight and the testing’s identified Factor weights is 0.76 
(sd=0.14). In addition to that, the numbering of factor is conserved 33 times out of 50. We can 
conclude that it is possible to retrieve a biologically relevant Factor from external dataset.  
 
 We tested the robustness to downsampling of the top predictive factor for different inclusion 
ratios (1, 0.9, 0.8, 0.7, 0.6, 0.5), in a 2 fold cross validation setting, with 100 MOFA iterations, 
repeated 30 times. In overall, the correlation between the top predictive factor of the training set 
and the corresponding factor in test set is conserved (Supplementary Figure 1). 
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B.2 Supplementary tables 
 
Omics  
layer 
Top  
Factors 
q-value  
Top genes contributing  
to each Factor 
Top enriched pathways using 
PCGSEA with Reactome 
Predicted 
Protein10006 
Factor 
1 
0.0014 
MT1X, FABP7, SFT2D2, 
TMEM26, VGLL1, MT1F, MAEL 
Processing of Capped 
Intron−Containing Pre−mRNA 
Antimicrobial peptides 
Factor 
6 
0.00071 
RPL26, RPL29, RPL34, RPL37, 
DPYSL5, BRI3BP, ABCA2, 
GABARAP 
Peptide chain elongation 
mRNA15107 
Factor 
2 
0.0025 
FOXA1, LBR, CDCA7, GATA3, 
PRKX, B3GNT5, MSN 
Cell Cycle, Mitotic Prometaphase,  
RHO GTPases Activate Formins 
Predicted 
Protein10006 
       +  
mRNA15107 
Factor 
2 
0.0050 
Protein view: TMEM26, 
TMEM259, SFT2D2 
mRNA view: TTK, SUV39H2, 
SRPK1, WDR43, CDCA8 
Protein view: Mitotic Prometaphase 
mRNA view: Cell Cycle, Mitotic 
Prometaphase 
Factor 
4 
0.044 
Protein view: SULT1E1, 
ARGLU1, AKR1B10, ING4, 
CEACAM5 
mRNA view: NRF1, RALB, 
DFFB 
Protein view: Extracellular matrix 
organization 
mRNA view: Degradation of DVL, 
Hh mutants abrogate ligand 
secretion 
Factor 
6 
0.0071 
Protein view: RPL34, RPL37, 
GABARAP 
mRNA view: HCFC1 
Protein view: Peptide chain 
elongation 
mRNA view: Peptide chain 
elongation 
 
Supplementary Table 1: Top predictive Factors and their functional characterization. We 
applied MOFA algorithm on protein, mRNA and a combination of both. The algorithm is run 20 
times and the best model is chosen based on highest Evidence Lower Bound (ELBO). For each 
predictive factor of survival, we showed relevant pathways ranked in top 3. The top contributing 
genes of each factor are those ranked in top 10 and with at least one Pubmed association with 
the keywords “breast cancer”. The genes in bold are those described in the result section. For 
the combination of protein and mRNA, we described for each view (protein and mRNA), the 
enriched pathways and top weighted genes. 
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B.3 Supplementary figures 
 
 
Supplementary Figure 1: MOFA robustness to downsampling. For each ratio of the total 
number of samples, we identify the top predictive Factor in the training set and retrieve the 
corresponding factors in the test set. 
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